论文部分内容阅读
目的探讨53BP1在乳腺癌组织中的表达及其与乳腺癌临床分期和病理分级的关系。方法采用免疫荧光法检测48例乳腺癌组织中53BP1的表达情况,并结合患者临床病理资料分析它们之间的关系。结果在20例正常乳腺组织中53BP1均表达稳定型;48例乳腺癌标本中未见稳定型和低DNA损伤反应(DDR)型,但见53BP1表达缺失10例(20.8%),高DDR型14例(14/48,29.2%),强DDR型24例(24/48,50%)。除缺失表达的10例外,在乳腺癌各临床分期中53BP1的表达差异无统计学意义(P>0.05);在35例乳腺浸润型导管癌各病理分级之间53BP1的表达差异有统计学意义(P<0.05),并且病理分级越高,53BP1表达强DDR型越多(rs=0.4955,P=0.0025)。结论53BP1的缺失表达可考虑其作为肿瘤抑制因子,而53BP1的聚集程度可以作为反映乳腺癌恶性潜能的生物学指标。
Objective To investigate the expression of 53BP1 in breast cancer and its relationship with clinical stage and pathological grade of breast cancer. Methods The expression of 53BP1 in 48 cases of breast cancer was detected by immunofluorescence. The relationship between them was analyzed according to the clinicopathological data. Results The expression of 53BP1 was stable in 20 normal breast tissues. No stable or low DNA damage response (DDR) was observed in 48 specimens of breast cancer. However, the expression of 53BP1 was not found in 10 (20.8%) and high DDR 14 Cases (14/48, 29.2%), strong DDR 24 cases (24/48, 50%). In addition to the lack of expression of 10 cases, the expression of 53BP1 was not significantly different in all clinical stages of breast cancer (P> 0.05). The expression of 53BP1 in 35 breast invasive ductal carcinomas was significantly different P <0.05), and the higher the pathological grade, the stronger the expression of 53BP1 in DDR (rs = 0.4955, P = 0.0025). Conclusion The deletion of 53BP1 can be considered as a tumor suppressor, while the degree of aggregation of 53BP1 can be used as a biological indicator to reflect the malignant potential of breast cancer.